2010 - TTS International Congress


This page contains exclusive content for the member of the following sections: TTS. Log in to view.

Kidney Chronic Graft Injury

55.75 - Early kidney allograft function in the UGT1A9 98T>C SNP carriers

Presenter: Joanna, Pazik, Warsaw, Poland
Authors: Pazik J., Ołdak M., Dąbrowski M., Lewandowski Z., Pazik J., Sitarek E., Grochowiecki T., Chmura A., Płoski R., Malejczyk J., Durlik M.

EARLY KIDNEY ALLOGRAFT FUNCTION IN THE UGT1A9 98T>C SNP CARRIERS

KIDNEY - CHRONIC GRAFT INJURY

J. Pazik1, M. O?dak2, M. D?browski2, Z. Lewandowski3, J. Pazik4, E. Sitarek5, T. Grochowiecki6, A. Chmura7, R. P?oski8, J. Malejczyk2, M. Durlik5
1Dept Of Transplantation Medicine And Nephrology, Warsaw Medical School, Warsaw/POLAND, 2Histology And Embryology, Medical University of Warsaw, Warsaw/POLAND, 3Dept Of Epidemiology, Medical University, Warsaw/POLAND, 4Department Of Transplantation Medicine And Nephrology, Medical University, Warsaw/POLAND, 5Dept Of Transplantation Medicine And Nephrology, Medical University of Warsaw, Warsaw/POLAND, 6Dept Of General, Vascular And Transplantation Surgery, Medical University of Warsaw, Warsaw/POLAND, 7Dept Of General And Transplantation Surgery, Medical University of Warsaw, Warsaw/POLAND, 8Forensic Medicine, Medical University of Warsaw, Warsaw/POLAND

Body: Introduction: UDP-glucuronosyltransferases (UGTs) are group of enzymes involved in the detoxification and excretion of many xeno- and endobiotics. In kidney allograft recipients UGT1A9 polymorphisms were shown to influence mycophenolate mophetil exposition. Study aim: to evaluate the association of the key clinical features of kidney post-transplant course and UGT1A9 SNPs 2152C>T, 275 T>A, 98T>C, known to influence enzyme expression and mycophenolic acid exposition. Patients and methods: In 106 kidney allograft recipients remaining on immunosuppressive regimens based on mycophenolate mophetil and either cyclosporine A or tacrolimus, DNA was extracted from blood samples by a standard salting out method. UGT1A9 2152C>T, 275 T>A, 98T>C genetic variants were genotyped by specific PCR sequence amplification followed by restriction fragment length polymorphism (PCR-RFLP) analysis. The associations between listed SNPs and kidney allograft function – expressed as GFR and/or proteinuria existence, acute rejection frequency and severity, infectious complications, PTDM occurrence, WBC, RBC and platelet counts in preselected time-points were evaluated. Statistical analysis was performed using GLM Procedure of SAS System and Fisher’s Exact Test. Results: In individuals carrying allele C of UGT1A9 98T>C SNP graft function (expressed as eGFRC&G) 1 month after engraftment was 43.7 vs 54.1ml/min/1.73m2 in non-carriers (p=ns), while at 3 month 42.4 vs 63.5 (p=0.009), at 6 months 66.9 vs 48.4 (p=0.029), and at 12 months 68.0 vs 43.7 (p=0.025 ). The differences in filtration rates increased with time, formed a plateau in variant C carriers and increased in non-carriers (p<0.0338). UGT1A9 98T>C SNP allel C presence enhanced risk of proteinuria at 1 months (50% vs 15,4% ; p=0.065) and at 2 month (50 vs 10 %; p=0.026) after engraftment. Conclusions: UDP gluculonylotransferase polimorphisms are intensely evaluated as potentially influencing mycophenolic acid metabolism, and indirectly it’s effectiveness in acute rejection prophylaxis. Our data show that polymorphisms diminishing UGT1A9 activity influence kidney allograft function, probably in more complex and until yet undefined mechanism.

Disclosure: All authors have declared no conflicts of interest.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada